

# Maria K Houtchens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/515323/publications.pdf>

Version: 2024-02-01

35  
papers

936  
citations

471371

17  
h-index

454834

30  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1008  
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Multiple Sclerosis During Pregnancy and the Reproductive Years. <i>Obstetrics and Gynecology</i> , 2014, 124, 1157-1168.	1.2	109
2	COVID-19 mRNA vaccination leading to CNS inflammation: a case series. <i>Journal of Neurology</i> , 2022, 269, 1093-1106.	1.8	87
3	Multiple sclerosis and pregnancy: therapeutic considerations. <i>Journal of Neurology</i> , 2013, 260, 1202-1214.	1.8	81
4	Pregnancy rates and outcomes in women with and without MS in the United States. <i>Neurology</i> , 2018, 91, e1559-e1569.	1.5	64
5	Sex effects across the lifespan in women with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093616.	1.5	58
6	COVID-19 in teriflunomide-treated patients with multiple sclerosis. <i>Journal of Neurology</i> , 2020, 267, 2790-2796.	1.8	56
7	Pregnancy and Multiple Sclerosis. <i>Seminars in Neurology</i> , 2007, 27, 434-441.	0.5	43
8	Contraception for women with multiple sclerosis: Guidance for healthcare providers. <i>Multiple Sclerosis Journal</i> , 2017, 23, 757-764.	1.4	41
9	Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. <i>Neurology</i> , 2018, 91, e1570-e1578.	1.5	40
10	Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 32, 54-63.	0.9	37
11	Multiple sclerosis in men: management considerations. <i>Journal of Neurology</i> , 2016, 263, 1263-1273.	1.8	30
12	No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. <i>BMC Neurology</i> , 2013, 13, 73.	0.8	26
13	Multiple Sclerosis and Pregnancy. <i>Clinical Obstetrics and Gynecology</i> , 2013, 56, 342-349.	0.6	26
14	Clinical and Radiologic Disease Activity in Pregnancy and Postpartum in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	24
15	Contraceptive use among women with multiple sclerosis: a systematic review. <i>Contraception</i> , 2016, 94, 612-620.	0.8	23
16	A case for gender-based approach to multiple sclerosis therapeutics. <i>Frontiers in Neuroendocrinology</i> , 2018, 50, 123-134.	2.5	19
17	Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	19
18	Menopause in multiple sclerosis: therapeutic considerations. <i>Journal of Neurology</i> , 2014, 261, 1257-1268.	1.8	18

#	ARTICLE	IF	CITATIONS
19	Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review. <i>Frontiers in Neurology</i> , 2021, 12, 554375.	1.1	18
20	Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab. <i>Journal of Neurology</i> , 2021, 268, 3592-3594.	1.8	16
21	Live birth rates, infertility diagnosis, and infertility treatment in women with and without multiple sclerosis: Data from an administrative claims database. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102541.	0.9	15
22	Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2018, 392, 94-99.	0.3	14
23	MRI activity in MS and completed pregnancy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	13
24	Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. <i>International Journal of Neuroscience</i> , 2017, 127, 971-980.	0.8	12
25	Reproductive Issues in MS. <i>Seminars in Neurology</i> , 2017, 37, 632-642.	0.5	8
26	Fingolimod-Associated Intracerebral Lymphoproliferative Disorder. <i>American Journal of Therapeutics</i> , 2019, 26, e481-e484.	0.5	6
27	A New England COVID-19 Registry of Patients With CNS Demyelinating Disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1046.	3.1	6
28	Risk factors for peripartum depression in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 970-979.	1.4	5
29	Canadian Multiple Sclerosis Pregnancy Study (CANPREG-MS): Rationale and Methodology. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 109-114.	0.3	4
30	Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 79-89.	1.4	4
31	Understanding Fluctuations of Multiple Sclerosis across the Menstrual Cycle. <i>International Journal of MS Care</i> , 2000, 2, 6-15.	0.4	4
32	Pregnancy Management in Multiple Sclerosis and Other Demyelinating Diseases. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 12-33.	0.4	4
33	Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103700.	0.9	4
34	Peripartum disease activity in moderately and severely disabled women with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211049.	0.5	2
35	It is time to conduct phase 3 clinical trials of sex hormones in MS – No. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1415-1417.	1.4	0